MA43704A - Liraglutide dans des états cardio-vasculaires - Google Patents

Liraglutide dans des états cardio-vasculaires

Info

Publication number: MA43704A
Authority: MA; Morocco
Prior art keywords: liraglutide; cardiovascular conditions; cardiovascular; conditions
Prior art date: 2016-03-04

Application number

MA043704A

Other languages

English (en)

Inventor

Kajsa Kvist

Søren Rasmussen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-04

Filing date

2017-03-03

Publication date

2021-04-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43704(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-03-03 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2021-04-14 Publication of MA43704A publication Critical patent/MA43704A/fr

Links

YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title 1
108010019598 Liraglutide Proteins 0.000 title 1
230000002526 effect on cardiovascular system Effects 0.000 title 1
229960002701 liraglutide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

MA043704A 2016-03-04 2017-03-03 Liraglutide dans des états cardio-vasculaires MA43704A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP16158739		2016-03-04
EP16173917		2016-06-10
EP16001329		2016-06-13
US15/401,651 US9968659B2 (en)	2016-03-04	2017-01-09	Liraglutide in cardiovascular conditions

Publications (1)

Publication Number	Publication Date
MA43704A true MA43704A (fr)	2021-04-14

Family

ID=59723004

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043704A MA43704A (fr)	2016-03-04	2017-03-03	Liraglutide dans des états cardio-vasculaires

Country Status (24)

Country	Link
US (2)	US9968659B2 (fr)
EP (1)	EP3423082B1 (fr)
JP (1)	JP6940512B2 (fr)
KR (1)	KR102417455B1 (fr)
CN (2)	CN108778317A (fr)
AU (2)	AU2017225841A1 (fr)
BR (1)	BR112018067344A2 (fr)
CA (1)	CA3013532C (fr)
CL (1)	CL2018002515A1 (fr)
DK (1)	DK3423082T5 (fr)
ES (1)	ES2893755T3 (fr)
HR (1)	HRP20211492T1 (fr)
HU (1)	HUE055844T2 (fr)
IL (1)	IL261169B (fr)
MA (1)	MA43704A (fr)
MX (1)	MX2018010097A (fr)
MY (1)	MY195657A (fr)
PH (1)	PH12018501844A1 (fr)
PL (1)	PL3423082T3 (fr)
RS (1)	RS62501B1 (fr)
RU (1)	RU2745604C2 (fr)
SI (1)	SI3423082T1 (fr)
WO (1)	WO2017149112A1 (fr)
ZA (1)	ZA201805538B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9968659B2 (en)	2016-03-04	2018-05-15	Novo Nordisk A/S	Liraglutide in cardiovascular conditions
CA3056663C (fr)	2019-04-05	2022-10-18	Jeffrey S. RIESMEYER	Utilisation du dulaglutide pour reduire le risque d'evenement cardiovasculaire chez les patients atteints du diabete de type 2
WO2022127868A1 (fr) *	2020-12-16	2022-06-23	The Chinese University Of Hong Kong	Méthode d'inversion du déclin fonctionnel du cerveau vieillissant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5808203A (en)	1997-05-12	1998-09-15	Medrad, Inc.	Fluid pressure measurement devices
JP2005535569A (ja) *	2002-04-04	2005-11-24	ノボ・ノルデイスク・エー／エス	Ｇｌｐ−１アゴニスト及び心臓血管合併症
KR101243648B1 (ko) *	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US20080125361A1 (en) *	2004-11-12	2008-05-29	Novo Nordisk A/S	Stable Formulations Of Peptides
WO2009030738A1 (fr) *	2007-09-05	2009-03-12	Novo Nordisk A/S	Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP2012522015A (ja)	2009-03-27	2012-09-20	ブリストル−マイヤーズスクイブカンパニー	Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法
WO2011140176A1 (fr)	2010-05-04	2011-11-10	Glaxosmithkline Llc	Méthodes de traitement ou de prévention de troubles cardiovasculaires, et de fourniture d'une protection cardiovasculaire
EP3725325B1 (fr)	2010-06-24	2023-05-31	Boehringer Ingelheim International GmbH	Traitement du diabète
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US20130172244A1 (en)	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
EP3685839A1 (fr)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
EP4151218A1 (fr)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
WO2013174768A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans le traitement du diabète auto-immun, notamment du lada
CN103893744B (zh) *	2012-12-24	2017-12-19	杭州九源基因工程有限公司	一种治疗糖尿病的药物制剂及其制备方法
CN110075098A (zh)	2013-03-15	2019-08-02	勃林格殷格翰国际有限公司	利格列汀在心脏和肾脏保护性抗糖尿病治疗中的用途
CN105283187A (zh)	2013-06-14	2016-01-27	勃林格殷格翰国际有限公司	用于治疗糖尿病及其并发症的二肽基肽酶-4抑制剂
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
WO2016019587A1 (fr)	2014-08-08	2016-02-11	Merck Sharp & Dohme Corp.	Composés antidiabétiques bicycliques condensés [7, 6]
US9968659B2 (en)	2016-03-04	2018-05-15	Novo Nordisk A/S	Liraglutide in cardiovascular conditions

2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active IP Right Grant
- 2017-03-03 CA CA3013532A patent/CA3013532C/fr not_active Expired - Fee Related
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/fr active Application Filing
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh active Pending
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/fr active Active
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
- 2017-03-03 MX MX2018010097A patent/MX2018010097A/es unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-08-30 PH PH12018501844A patent/PH12018501844A1/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending

Also Published As

Publication number	Publication date
HUE055844T2 (hu)	2021-12-28
IL261169A (en)	2018-10-31
IL261169B (en)	2019-11-28
MY195657A (en)	2023-02-03
DK3423082T5 (da)	2023-02-06
SI3423082T1 (sl)	2021-10-29
PH12018501844A1 (en)	2019-05-15
CA3013532A1 (fr)	2017-09-08
EP3423082B1 (fr)	2021-08-04
PL3423082T3 (pl)	2021-12-27
AU2024201937A1 (en)	2024-04-11
WO2017149112A1 (fr)	2017-09-08
AU2017225841A1 (en)	2018-08-23
CN108778317A (zh)	2018-11-09
BR112018067344A2 (pt)	2019-01-08
RS62501B1 (sr)	2021-11-30
HRP20211492T1 (hr)	2021-12-24
RU2745604C2 (ru)	2021-03-29
CN116327897A (zh)	2023-06-27
EP3423082A1 (fr)	2019-01-09
DK3423082T3 (da)	2021-10-11
US9968659B2 (en)	2018-05-15
US20180236038A1 (en)	2018-08-23
MX2018010097A (es)	2018-11-09
US20170252408A1 (en)	2017-09-07
CA3013532C (fr)	2019-07-23
ZA201805538B (en)	2020-05-27
CL2018002515A1 (es)	2018-11-09
JP2019507174A (ja)	2019-03-14
ES2893755T3 (es)	2022-02-10
KR20180114168A (ko)	2018-10-17
KR102417455B1 (ko)	2022-07-06
JP6940512B2 (ja)	2021-09-29
RU2018134061A3 (fr)	2020-07-15
RU2018134061A (ru)	2020-04-06

Publication	Publication Date	Title
DK3137587T3 (da)	2019-01-02	Detergentsammensætning
DK3406697T3 (da)	2020-08-31	Detergentsammensætning
DE112015003457A5 (de)	2017-04-13	Al-Gusslegierung
DK3245331T3 (da)	2023-01-09	Fortøjningselement
DK3448416T3 (da)	2022-10-03	Semaglutid ved kardiovaskulære tilstande
KR20180085035A (ko)	2018-07-25	세탁기
DE112016001806A5 (de)	2018-02-08	Bausatz
DK3253755T3 (da)	2020-09-28	Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
BR112017009319A2 (pt)	2017-12-19	bicicleta
MA43704A (fr)	2021-04-14	Liraglutide dans des états cardio-vasculaires
PT3423082T (pt)	2021-11-12	Liraglutida em condições cardiovasculares
UA32461S (uk)	2016-06-24	Лінійка
CU20150007S4 (es)	2016-03-31	Trofeo
UY4439S (es)	2016-06-01	Trofeo
FI20155947A (fi)	2017-06-15	Kilpijärjestely
UA32448S (uk)	2016-06-24	Довгогубці
UA32447S (uk)	2016-06-24	Довгогубці
UA32877S (uk)	2016-09-12	Рівень
UA33375S (uk)	2016-11-25	Шифер
ES1141311Y (es)	2015-10-05	Tendedero
TH1601002981A (th)	2017-07-20	องค์ประกอบซักผ้า
TH1601002982A (th)	2017-07-20	องค์ประกอบซักผ้า
FI11303U1 (fi)	2016-07-01	Sihtisylinteri
FI20155685A (fi)	2017-03-26	Myyntivirta
FI11109U1 (fi)	2016-01-21	Juomatölkki